# Study of GV20-0251 in Participants With Solid Tumor Malignancies

Source: https://onco.cc/trials/nct07070518/  
OnCo record `nct07070518` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer, melanoma, hepatocellular carcinoma and small-cell lung cancer, run by GV20 Therapeutics, now recruiting.

## Summary

Study of GV20-0251 in Participants With Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT07070518 by GV20 Therapeutics, with 350 participants planned, started 2025-07-11 and due to reach its primary completion in 2027-07-16. Interventions recorded: GV20-0251.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07070518
- Phase: 1/2
- Setting: An Open-Label Phase 1/2A Study of GV20-0251 in Participants With Advanced and/or Refractory Solid Tumor Malignancies
- Sponsor: GV20 Therapeutics
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT07070518: https://clinicaltrials.gov/study/NCT07070518

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07070518.json